Core Insights - Several A-share companies reported significant profit growth in their Q3 earnings, indicating a positive trend in the market [2] Company Performance Summaries Jiangshan Co., Ltd. (江山股份) - Q3 revenue reached 1.157 billion yuan, a year-on-year increase of 2.75% - Net profit attributable to shareholders was 86.73 million yuan, up 11890.01% year-on-year - For the first three quarters, revenue was 4.516 billion yuan, a 5.20% increase, and net profit was 425.20 million yuan, up 147.91% [3][4] Yongmaotai (永茂泰) - Q3 revenue was 1.655 billion yuan, a 59.65% increase year-on-year - Net profit attributable to shareholders was 30.41 million yuan, up 6319.92% - For the first three quarters, revenue was 4.275 billion yuan, a 54.66% increase, and net profit was 50.18 million yuan, up 39.58% [4][5] Nanjing Public Utilities (南京公用) - Q3 revenue reached 3.102 billion yuan, a year-on-year increase of 165.53% - Net profit attributable to shareholders was 84.62 million yuan, up 2492.12% - For the first three quarters, revenue was 5.968 billion yuan, a 64.06% increase, and net profit was 115.90 million yuan, up 903.99% [5][6] Daheng Technology (大恒科技) - Q3 revenue was 453 million yuan, a 26.86% increase year-on-year - Net profit attributable to shareholders was 71.48 million yuan, up 1960.72% - For the first three quarters, revenue was 1.296 billion yuan, a 13.11% increase, and net profit was 68.74 million yuan [6][7] Huisheng Biological (回盛生物) - Q3 revenue reached 437 million yuan, a 22.76% increase year-on-year - Net profit attributable to shareholders was 70.72 million yuan, up 1575.79% - For the first three quarters, revenue was 1.260 billion yuan, a 58.92% increase, and net profit was 187.91 million yuan, up 494.28% [7][8] Delinhai (德林海) - Q3 revenue was 185 million yuan, a 94.96% increase year-on-year - Net profit attributable to shareholders was 48.73 million yuan, up 1322.74% - For the first three quarters, revenue was 29.30 million yuan, a 2.39% decrease, and net profit was 45.64 million yuan, up 61.87% [8][9] Gaode Infrared (高德红外) - Q3 revenue reached 1.134 billion yuan, a 71.07% increase year-on-year - Net profit attributable to shareholders was 401 million yuan, up 1143.72% - For the first three quarters, revenue was 3.068 billion yuan, a 69.27% increase, and net profit was 581.94 million yuan, up 1058.95% [9][10] Deepin Technology (深信服) - Q3 revenue was 2.116 billion yuan, a 9.86% increase year-on-year - Net profit attributable to shareholders was 147 million yuan, up 1097.40% - For the first three quarters, revenue was 5.125 billion yuan, a 10.62% increase, with a net profit loss of 80.56 million yuan [10][11]

Group 1 - Jinpan Technology reported a net profit of 486 million yuan for the first three quarters, a year-on-year increase of 20.27%, with total revenue of 5.194 billion yuan, up 8.25% [1] - Saisir announced the maximum price for its H-share issuance at 131.5 HKD per share, with the public offering starting on the same day and expected to end on October 31 [1] - Jinghua Laser plans to invest approximately 200 million yuan in a new project to produce 20,000 tons of UV laser platinum embossed anti-counterfeiting materials [2] Group 2 - Zhenyu Technology intends to invest 2.11 billion yuan in a project for robots and precision structural components, to be developed in three phases from 2025 to 2030 [3] - Qianyuan Power reported a net profit of 493 million yuan for the first three quarters, a year-on-year increase of 85.74%, with total revenue of 2.169 billion yuan, up 47.99% [4] - Haohua Energy's net profit decreased by 50.5% to 554 million yuan, with total revenue of 6.307 billion yuan, down 7.85% [7] Group 3 - Kangtai Biological's net profit fell by 86% to 49.16 million yuan, with total revenue of 2.063 billion yuan, up 2.24% [8] - Huafeng Aluminum reported a net profit of 896 million yuan for the first three quarters, a year-on-year increase of 3.24%, with total revenue of 9.109 billion yuan, up 18.63% [10] - Beiyuan Group's net profit decreased by 10.88% to 214 million yuan, with total revenue of 6.762 billion yuan, down 9.91% [12] Group 4 - Noying Co. reported a net profit of 450 million yuan for the first three quarters, a year-on-year decrease of 22.95%, with total revenue of 31.562 billion yuan, up 2.01% [14] - Chuanhua Zhili's net profit increased by 168.36% to 637 million yuan, despite a revenue decline of 2.74% to 18.84 billion yuan [16] - Jiangsu Sop's net profit decreased by 39.21% to 126 million yuan, with total revenue of 4.661 billion yuan, down 5.74% [18] Group 5 - Yiling Pharmaceutical's net profit increased by 80.33% to 1 billion yuan, with total revenue of 5.868 billion yuan, down 7.82% [20] - Hengwei Technology's net profit decreased by 50.16% to 39.01 million yuan, with total revenue of 739 million yuan, up 16.14% [22] - Gaode Infrared reported a net profit increase of 1058.95% to 582 million yuan, with total revenue of 3.068 billion yuan, up 69.27% [24] Group 6 - Sanxia Water reported a net profit decrease of 8.53% to 351 million yuan, with total revenue of 7.611 billion yuan, down 6.06% [26] - Junda Co. reported a net loss of 419 million yuan for the first three quarters, with total revenue of 5.682 billion yuan, down 30.72% [28] - Shanghai Energy's net profit decreased by 59.22% to 255 million yuan, with total revenue of 5.64 billion yuan, down 22.03% [30] Group 7 - Haizheng Biomaterials reported a net profit decrease of 85.34% to 490,570 yuan, with total revenue of 621 million yuan, down 5.74% [32] - Huisheng Lithium reported a net loss of 103 million yuan, with total revenue of 539 million yuan, up 62.29% [34] - Weicet Technology's net profit increased by 226.41% to 202 million yuan, with total revenue of 1.083 billion yuan, up 46.22% [36] Group 8 - Mengjie Co. reported a net profit increase of 28.69% to 26.52 million yuan, with total revenue of 1.099 billion yuan, down 7.97% [38] - Qingdao Beer terminated its acquisition of 100% equity in Jimo Yellow Wine due to unmet conditions [40] - Sifang Precision plans to issue H-shares and list on the Hong Kong Stock Exchange [42]

Core Viewpoint - Multiple A-share companies have reported significant growth in their performance for the third quarter, indicating a positive trend in various sectors of the market [2]. Group 1: Company Performance Highlights - Jiangshan Co., Ltd. reported a third-quarter revenue of 1.157 billion yuan, a year-on-year increase of 2.75%, with a net profit attributable to shareholders of 86.73 million yuan, up 11890.01% [2][3]. - Yongmaotai's third-quarter revenue reached 1.655 billion yuan, reflecting a 59.65% year-on-year growth, and a net profit of 30.41 million yuan, an increase of 6319.92% [5][6]. - Nanjing Public Utilities achieved a third-quarter revenue of 3.102 billion yuan, a 165.53% increase year-on-year, with a net profit of 84.62 million yuan, up 2492.12% [7]. - Daheng Technology reported a third-quarter revenue of 453 million yuan, a 26.86% increase, with a net profit of 71.48 million yuan, up 1960.72% [8]. - Gaode Infrared's third-quarter revenue was 1.134 billion yuan, a 71.07% increase, with a net profit of 401 million yuan, up 1143.72% [10]. Group 2: Factors Contributing to Growth - Jiangshan's performance improvement was attributed to increased sales volume of certain products, reduced costs leading to higher gross margins, and investment income from the sale of stocks [2]. - Yongmaotai's net profit growth was driven by substantial revenue increases and enhanced operational management, leading to improved profit margins in its automotive parts business [5]. - Nanjing Public Utilities' significant growth was primarily due to the increased volume of property projects delivered compared to the previous year [7]. - Daheng Technology's growth was supported by improved performance in machine vision and digital broadcasting systems, along with gains from financial assets [8]. - Gaode Infrared's revenue surge was linked to the recovery of delayed project deliveries and expansion into civilian product markets [10].

每经头条（nbdtoutiao）——独家丨民营船王入主杉杉集团横生枝节 重整联合体浮现神秘组局人 截至发稿，回盛生物市值为44亿元。 每经AI快讯，回盛生物（SZ 300871，收盘价：21.69元）10月27日晚间发布三季度业绩公告称，2025年 前三季度营收约12.6亿元，同比增加58.92%；归属于上市公司股东的净利润约1.88亿元，同比增加 494.28%；基本每股收益1.0134元，同比增加452.61%。 （记者 王晓波） ...

证券代码：300871 证券简称：回盛生物 公告编号：2025-100 武汉回盛生物科技股份有限公司 关于2025年前三季度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、本次计提资产减值准备情况概述 （一）计提资产减值准备原因 根据《企业会计准则》及武汉回盛生物科技股份有限公司（以下简称"公 司"）会计政策、会计估计等相关规定，基于谨慎性原则，为客观、公允地反 映公司财务状况、资产价值和经营成果，公司对合并报表范围内截至 2025 年 9 月 30 日可能发生信用及资产减值损失的有关资产进行了减值测试，并对有 关资产减值的可能性进行了充分的评估和分析，计提了信用及资产减值准备。 （二）计提减值准备的资产范围和金额 | | 资产减值项目 | 本期发生金额 | | --- | --- | --- | | | 应收账款减值损失 | -484.18 | | 1.信用减值损失 | 其他应收款坏账损失 | 60.80 | | | 小计 | -423.38 | | | 存货跌价损失及合同履约成本减值损失 | -192.40 | | 2.资产减值 ...

证券代码：300871 证券简称：回盛生物 公告编号：2025-098 武汉回盛生物科技股份有限公司 第四届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 武汉回盛生物科技股份有限公司（以下简称"公司"）第四届董事会第二 次会议于 2025 年 10 月 27 日在公司会议室以现场结合通讯方式召开，本次会 议通知于 2025 年 10 月 24 日以电子邮件及电话方式送达全体董事。本次应出 席董事 5 名，实际出席会议的董事 5 名，其中以通讯方式出席的董事 1 名。本 次会议由董事长张卫元先生主持，公司高级管理人员列席了本次会议，会议的 召集、召开和表决程序符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定。 二、董事会会议审议情况 经与会董事认真审议，通过了以下议案： （一）审议通过了《关于<2025 年第三季度报告>的议案》 公司董事会在全面审核《2025 年第三季度报告》后，一致认为：公司 2025 年第三季度报告编制和审核的程序符合相关法律法规，报告内容真实、准确、 完整地反映了公司 ...

Core Insights - The animal health sector experienced a rise of 1.56% on October 27, with Huisheng Biological leading the gains [1] - The Shanghai Composite Index closed at 3996.94, up 1.18%, while the Shenzhen Component Index closed at 13489.4, up 1.51% [1] Stock Performance Summary - Huisheng Biological (300871) closed at 21.69, up 4.53% with a trading volume of 105,300 shares and a turnover of 227 million yuan [1] - Xianfeng Holdings (002141) closed at 4.05, up 3.32% with a trading volume of 503,300 shares and a turnover of 203 million yuan [1] - Biological Shares (600201) closed at 11.08, up 2.88% with a trading volume of 444,500 shares and a turnover of 489 million yuan [1] - Other notable stocks include Shunlian Biological (688098) at 11.00, up 2.33%, and Ruipu Biological (300119) at 21.33, up 2.20% [1] Capital Flow Analysis - The animal health sector saw a net inflow of 91.28 million yuan from institutional investors, while retail investors experienced a net outflow of 1.02 billion yuan [2] - Major stocks like Biological Shares (600201) had a net inflow of 64.91 million yuan from institutional investors, while Huisheng Biological (300871) saw a net inflow of 24.29 million yuan [3] - Conversely, *ST Green Kang (002868) experienced a significant net outflow of 4.93 million yuan from institutional investors [3]

Financial Performance - The company's operating revenue for Q3 2025 reached ¥437,334,051.69, representing a year-on-year increase of 22.76%[5] - The net profit attributable to shareholders for the same period was ¥70,724,741.75, a significant increase of 1,575.79% compared to the previous year[5] - The net profit after deducting non-recurring gains and losses was ¥66,546,036.62, reflecting a 921.83% increase year-on-year[5] - The company reported a net profit of ¥188,484,725.84 for the first nine months of 2025, a 495.84% increase year-on-year[12] - Net profit for the current period was ¥188,484,725.84, compared to a net loss of ¥47,615,990.17 in the previous period, indicating a turnaround in profitability[24] - Earnings per share (EPS) for the current period was ¥1.0134, compared to a loss per share of ¥0.2874 in the previous period[25] - The company reported a total comprehensive income of ¥186,173,900.97, compared to a loss of ¥48,383,298.05 in the previous period[25] Assets and Liabilities - The total assets as of September 30, 2025, were ¥2,958,011,760.44, showing a decrease of 1.88% from the end of the previous year[5] - The company's total assets decreased from 3,014,682,865.02 yuan at the beginning of the period to 2,958,011,760.44 yuan at the end of the period, a reduction of approximately 1.87%[20] - The total liabilities decreased from 1,549,479,748.16 yuan to 839,938,116.60 yuan, a reduction of about 45.8%[20] - The total liabilities amounted to ¥839,938,116.60, while total equity reached ¥2,118,073,643.84, indicating a strong balance sheet[21] Cash Flow - The cash flow from operating activities for the year-to-date reached ¥181,515,060.75, a remarkable increase of 2,452.72%[5] - Cash inflow from operating activities totaled ¥991,584,938.53, an increase from ¥727,679,278.47 in the previous period[26] - The net cash flow from operating activities was $181,515,060.75, a significant increase from $7,110,643.63 in the previous period, indicating strong operational performance[27] - Cash outflows from investing activities totaled $639,792,156.12, compared to $659,840,673.74 in the prior period, reflecting a decrease in investment expenditures[27] - The net cash flow from financing activities was -$68,052,667.23, a decline from a positive cash flow of $29,649,582.00 in the previous period, suggesting increased financial strain[27] - The total cash and cash equivalents at the end of the period amounted to $152,827,248.69, up from $139,349,768.58 in the previous period, indicating improved liquidity[27] Shareholder Information - The largest shareholder, Wuhan Tongsheng Investment Co., Ltd., holds 40.92% of the shares, totaling 82,800,000 shares[16] - The company has a share repurchase account holding 753,600 shares, representing 0.37% of total shares[16] Research and Development - Research and development expenses for the first nine months of 2025 amounted to ¥54,023,597.12, up 38.69% from the same period last year[12] - Research and development expenses increased to ¥54,023,597.12 from ¥38,952,745.03, highlighting the company's commitment to innovation[24] Operational Efficiency - The weighted average return on equity for the year-to-date was 10.35%, an increase of 13.57% compared to the previous year[5] - The company experienced a 606.40% increase in tax payable, amounting to ¥19,924,558.62, primarily due to increased income tax obligations[10] - The company's cash flow from operating activities showed resilience despite overall cash flow challenges, reflecting operational efficiency improvements[27] Inventory and Receivables - The company's inventory increased from 248,164,158.72 yuan to 254,459,287.83 yuan, an increase of about 2.5%[19] - Accounts receivable rose from 368,367,475.80 yuan to 391,468,700.00 yuan, an increase of approximately 6.3%[18] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[24]

回盛生物公告，第三季度营收为4.37亿元，同比增长22.76%；净利润为7072.47万元，同比增长 1,575.79%。前三季度营收为12.6亿元，同比增长58.92%；净利润为1.88亿元，同比增长494.28%。 ...

Core Insights - The implementation of the integrated raw material and formulation strategy has significantly enhanced the company's competitiveness and profitability [2] - The company's active pharmaceutical ingredient (API) business revenue saw substantial growth compared to the same period last year [2] - The company is increasing its investment in microbial fermentation innovation to improve production efficiency and product quality [2] Business Strategy - The company is focusing on expanding its domestic and international market presence to boost capacity utilization [2] - Production plans are being arranged based on market demand, ensuring a responsive approach to changing conditions [2] - The company will disclose sales performance of its API business in its annual and semi-annual reports [2]